Printer Friendly

EXCIMER LASER PROCEDURE PROVIDES MEDICAL AND COST-SAVING ADVANTAGES FOR HEART DISEASE PATIENTS

 Interventional Cardiologists Achieve Greater Success Rates
 When Treating More Difficult Cases With Cool' Laser
 IRVINE, Calif., Feb. 4 /PRNewswire/ -- When excimer laser angioplasty is used by interventional cardiologists to clear blocked arteries in the heart, "it makes impossible cases possible and difficult cases easy," said Robert E. Wall, the chairman and chief executive officer of Advanced Interventional Systems (NASDAQ: LAIS), Wednesday at Piper Jaffray's Fifth Annual Cardiovascular Conference in New York.
 LAIS' system delivers micro-bursts of energy through specially designed catheters to remove blockages in coronary arteries created by the build-up of plaque. It is the first laser system for treating heart disease to receive approval from the federal Food and Drug Administration (FDA) for commercial marketing.
 The laser procedure utilizing the LAIS system, which is currently available in approximately 85 medical centers throughout the United States, provides many patients with significant medical and cost- saving advantages over both balloon angioplasty and bypass surgery, Wall said.
 "Since 1988, the clinical data has shown that laser angioplasty offers significant advantages over balloon angioplasty when blockages are severe. Complication rates are lower and success rates increase when the laser procedure is used to treat more difficult blockages," he said.
 "For many of these patients who might otherwise require open- heart surgery, the laser procedure offers an excellent alternative that costs significantly less. It is also less traumatic physically and psychologically."
 According to Wall, the excimer laser is superior to earlier lasers proposed for treating heart disease, in part, because it is a "cool" laser. The excimer laser utilizes a photochemical process rather than thermal mechanisms to remove plaque. It creates a clean, precise cut with no significant temperature change or damage to surrounding tissue.
 Although the "early adopters" of excimer laser angioplasty are among the leading cardiologists in the world, LAIS has encountered tentativeness in the marketplace throughout the past year, he said.
 "Pioneering state-of-the-art medical technology in today's regulatory environment is a serious challenge. And with the increasing pressure to hold down health care costs, hospitals must be thoroughly educated to understand the cost advantages of purchasing an excimer laser system. And, finally, we frequently are faced with the need to differentiate our technology from the disappointing results of earlier medical lasers that created thermal damage," he said.
 According to Wall, the company expects that revenues for the year ended Dec. 31, 1992, will be consistent with analysts' expectations of approximately $14 to $15 million. However, LAIS is likely to report an operating loss significantly higher than the projected loss of about $.70 per share as a result of two non-reoccurring events in the quarter ended Dec. 31, 1992.
 "We anticipate a one-time charge in the quarter ended Dec. 31, 1992, for an inventory reserve associated with the DYMER 200+ unit following the FDA's approval last month of the company's second generation LAISer II unit. We also expect to take a one-time charge for expenses incurred in the settlement of a patent dispute with Pillco Limited Partnership," he said.
 In January 1993, LAIS received FDA approval to commercially market its second generation laser unit, the LAISer II, which is expected to be available for shipment to hospitals by the end of the year. In the meantime, LAIS will continue to sell its DYMER 200+ system and provide customers the opportunity to trade up to the LAISer II unit when it becomes available.
 Wall said, "LAIS considers the recognition of both of these non- reocurring expenses in the fourth quarter as extremely conservative treatment of the company's financial statements. With these two expenses fully recognized in fiscal 1992, our operating results for 1993 and 1994 will more clearly reflect the health of the company."
 -0- 2/4/93
 /CONTACT: Connie McCluskey, director-Corporate Communications, 714-586-1342, or 714-581-8510, ext. 234/
 (LAIS)


CO: Advanced Interventional Systems ST: California IN: MTC SU:

EH -- LA019 -- 2892 02/04/93 10:41 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:645
Previous Article:THOMAS R. TIMMONS NAMED PRESIDENT, CEO AND DIRECTOR OF PIONEER BANCORP
Next Article:TARGET STORES WINS AD AGE 'RETAILER OF THE YEAR' AWARD AT 41ST ANNUAL RETAIL ADVERTISING CONFERENCE
Topics:


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM
LATEST DATA PRESENTED ON RECENTLY APPROVED CORONARY LASER ANGIOPLASTY DEVICE AT AMERICAN COLLEGE OF CARDIOLOGY MEETING
LAIS EXPANDS INTERNATIONAL MARKETING EFFORT
ADVANCED INTERVENTIONAL SYSTEMS FILES PATENT INFRINGEMENT CLAIM
EXCIMER LASER SURGERY TO CORRECT MYOPIA APPROVED FOR U.S. MARKET
FIRST FDA-APPROVED EXCIMER LASER PROCEDURES IN MINNESOTA PERFORMED AT PHILLIPS EYE INSTITUTE
PLC SYSTEMS ANNOUNCES FIRST HEART LASER SHIPMENT TO CHINA, THE WORLD'S LARGEST POTENTIAL HEART DISEASE MARKET
Spectranetics Corporation Reports Quarterly Revenues of $6.2 Million
Spectranetics' Excimer Laser Treatment Is Used Successfully in Two Cases at Cleveland Clinic to Treat Difficult Leg Artery Blockages.
Spectranetics' Laser Angioplasty Technology Cited as Cost-Effective Alternative to Competing Atherectomy Technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters